DTx’s coverage conundrum
Makers of digital therapeutics (DTx) are raising huge sums from investors to treat patients with everything from insomnia, to substance [...]
COVID-19 HEOR Researcher Discusses Pandemic Modeling
Models predicting the impact of pharmaceutical and non-pharmaceutical measures aimed at reducing the spread of COVID-19 have been developed throughout [...]
ISPOR Webinar on Statistical Considerations in Rare Disease Research
The Professional Society for Health Economics and Outcomes Research (ISPOR) will hold a webinar on June 2nd at 1:00 PM [...]
Johnson & Johnson RWE Expert Shares Thoughts on Transparency
In a recent interview, Jesse Berlin of Johnson & Johnson discusses how real world evidence (RWE) has shifted the research [...]
Biosimilar Market to Hit $178 Billion in 2024
In 2006, the European Medicines Agency approved its first biosimilar. Omnitrope was developed in cases of growth hormone deficiency. Now, [...]
Report on International Healthcare Systems Notes High Costs in United States and Equity Challenges
The Commonwealth Fund has published a report that provides a comprehensive look into healthcare systems around the world. In the [...]
HTAs Consider the Incorporation of RWE in Drug Assessments
A new edition of industry news highlights focuses on health technology assessments (HTAs) and their growing acceptance of real world [...]
ICER Announces Cloud-Based ICER Analytics Platform
The Institute for Clinical and Economic Review (ICER) has announced the launch of ICER Analytics. The new cloud-based tool is [...]
ISPOR Publishes Good Practices Report
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) task force has published its Good Practices Report. The purpose of [...]
Cytel Chief Data Officer Discuses HEOR and RWE
Cytel Chief Data Officer & Head of Europe Dr. Radek Wasiak discusses how Cytel has expanded to utilize health economics [...]
HealthVerity RWD Use Case Now Available
The use of real world data (RWD) in the synthetic control arm in clinical trials is becoming essential. HealthVerity provides [...]
Fate of Biogen’s Alzheimer’s Disease Drug Remains Uncertain
Biogen is awaiting the Food and Drug Administration’s decision regarding its Alzheimer’s disease drug, aducanumab. However, mixed data regarding the [...]
ICER Will Consider AstraZeneca Asthma Treatment
The Institute for Clinical and Economic Review (ICER) is set to evaluate AstraZeneca’s tezepelumab. ICER will consider the efficacy and [...]
FDA Office of Health Equity Leader Discusses Diversity in Clinical Trials
Associate Commissioner for Minority Health and Director of the Office of Minority Health and Health Equity (OMHHE) at the FDA RADM [...]
ISPOR Signal Virtual Event on Value and Pricing Strategies
ISPOR will host its second event in its new Signal series on June 25th, from 11:00 AM to 12:00 PM [...]
Managing Healthcare Risk Effectively During COVID-19
The COVID-19 pandemic has placed immense burden on healthcare systems. A new whitepaper, sponsored by Change Healthcare, provides insight into [...]
Optum Whitepaper on RWD in Rare Disease Research
Optum is offering a whitepaper that provides insight into how real world data (RWD) can accelerate rare disease research. The [...]
Woman to Woman Podcast Series Highlights Senior HEOR Researcher
Divya Yerraguntla hosts a podcast series that highlights the stories of women who have broken through barriers to succeed in [...]
ICER Reveals Final Evidence Report on Three Multiple Myeloma Therapies
The Institute for Clinical and Economic Review (ICER) has announced a Final Evidence Report evaluating three therapies for use in [...]
Podcast on Succeeding as a Woman in Biotech and Business
Erin Jewell Consulting offers a podcast series highlighting the stories of women from different industries. A new podcast featuring Darla [...]
Upcoming Webinar on Managing Unconscious Bias
Unconscious bias and microaggressions can lead to poor workplace culture and unhappy employees. A webinar will cover how to recognize [...]
Aetion Announces $212 Million in Total Funding as RWE Momentum Builds
Aetion raised an additional $110 million in Series C funding, making its total funding $212 million. The real world evidence [...]
HealthEconomics.Com President Leads Discussion on New Scientist.com’s Value, Evidence and Access Marketplace, Notes Substantial Cost Benefits
HealthEconomics.Com President Dr. Patti Peeples spoke with Scientist.com Category Directory Maria Negron and Senior Director of Business Development David Brown. [...]
IQVIA Guide on RWD Applications in Drug Development Pipeline
IQVIA has released an eBook detailing when it’s appropriate to use real world evidence (RWE) and real world data (RWD). [...]
Upcoming Discussion on the Role of AI in Healthcare, COVID-19, and Equity
STAT recently published a report on artificial intelligence (AI), noting potential benefits such as lower healthcare costs and earlier disease [...]